Nevirapine Sandoz

Nevirapine, the active ingredient in Nevirapine Sandoz, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is used to treat HIV‑1 infection as part of combination antiretroviral therapy in adults and children. GNH USA supplies Nevirapine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral medication that targets HIV‑1 replication. - HIV‑1 infection (adults): Reduces viral load when used with other antiretrovirals. - HIV‑1 infection (children): Improves immune function as part of pediatric combination regimens. - Prevention of mother‑to‑child transmission: Decreases risk of vertical HIV transmission when included in maternal therapy.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional upset stomach. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools. - Headache: mild to moderate pain. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic failure: signs of liver injury such as jaundice. - Severe hypersensitivity: swelling, fever, and systemic symptoms. - Neutropenia: low white‑blood‑cell count increasing infection risk. - Hepatotoxicity: elevated liver enzymes indicating liver stress.

Before prescribing Nevirapine, clinicians should consider several safety measures. - Liver monitoring: check hepatic function before and during therapy. - Rash assessment: evaluate any skin changes promptly. - Hypersensitivity history: avoid in patients with known allergy to NNRTIs. - Pregnancy counseling: discuss potential risks with women of child‑bearing potential. - Drug interaction review: assess concomitant medications for possible interactions. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nevirapine can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Rifampicin: reduces Nevirapine plasma levels, compromising efficacy. - St. John’s wort: induces metabolism, lowering drug exposure. - Protease inhibitors (e.g., ritonavir): may increase toxicity risk.

Moderate Interactions (Monitor Closely): - Efavirenz: combined NNRTIs can increase adverse skin reactions. - Zidovudine: may enhance hematologic toxicity, requiring blood count monitoring.